The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

The company is positioning BE-Smart for near-term commercialization, targeting the $10 billion esophageal disease testing market. With dual compatibility across standard biopsy methods, BE-Smart is ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...

Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...